炎症因子评分对小细胞肺癌预后的辅助评估价值

Auxiliary diagnostic potential of inflammatory factor scores in evaluating the prognosis of small cell lung cancer

目的探讨炎症因子评分对小细胞肺癌患者预后的辅助评估作用,及其在临床实践中的应用价值。方法筛选118例小细胞肺癌患者的临床资料,统计改良格拉斯哥预后评分(m GPS)、中性粒细胞-淋巴细胞比值(NLR)、血小板-淋巴细胞比值(PLR)和单核细胞-淋巴细胞比值(MLR),运用Kaplan-Meier生存分析和Cox风险比例回归模型来回顾性分析其用于近期疗效和远期预后评估的价值。结果m GPS、NLR、MLR高分组患者处于广泛期和发生远处转移的比例较高(P<0.05),予以标准治疗后,m GPS、NLR、PLR和MLR低分组客观有效率和疾病控制率明显优于高分组(P<0.05)。m GPS、NLR、PLR和MLR高分组与低分组肿瘤无进展生存期(PFS)和总生存期(OS)的差异有统计学意义(P<0.05)。多因素预后分析提示,m GPS是小细胞肺癌预后的独立危险因素(HR=0.603,95%CI:0.373-0.973,P=0.038)。结论炎症因子评分m GPS、NLR、PLR和MLR均与小细胞肺癌预后有关,其中m GPS评分可作为评估小细胞肺癌预后的独立危险因素。

Objective To explore the auxiliary diagnostic potentials of inflammatory factors in evaluating the prognosis of patients with small cell lung cancer(SCLC)and its value in clinical practice.Methods A total of 118 SCLC patients were selected and their clinical data were collected to analyze their modified Glasgow prognostic score(m GPS),neutrophil-lymphocyte ratio(NLR),platelet-lymphocyte ratio(PLR)and monocyte-lymphocyte ratio(MLR).Their potentials in evaluating the short-term effectiveness and long-term prognosis were retrospective analyzed by Kaplan-Meier survival analysis and Cox’s proportional hazard regression model.Results Patients with high scores of m GPS,NLR and MLR presented a higher proportion of extensive stage and distant metastasis(P<0.05).After standard treatment,patients with low scores of m GPS,NLR,PLR and MLR presented remarkably improvement in the objective response rate(ORR)and disease control rate(DCR),compared with those with high scores(P<0.05).There were no statistical differences in the progression-free survival(PFS)and overall survival(OS)between the high and low m GPS,NLR,PLR and MLR score groups(P<0.05).Multivariate prognosis analysis showed that m GPS was an independent risk prognostic factor for SCLC(HR=0.603,95%CI:0.373-0.973,P=0.038).Conclusions Inflammatory factors such as m GPS,NLR,PLR,and MLR are associated with the prognosis of SCLC,where m GPS is an independent risk factor for the prognosis of SCLC.